Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide
NCT ID: NCT01678781
Last Updated: 2013-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
607 participants
OBSERVATIONAL
2012-07-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
One patient group
Patients suffering from irritable bowel syndrome
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Specific contraindications to mebeverine hydrochloride or pinaverium bromide
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHILTERN International GmbH
UNKNOWN
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guenter Krause
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site reference ID/Investigator# 94519
Beijing, , China
Site reference ID/Investigator# 94521
Guangzhou, , China
Site reference ID/Investigator# 95475
Guangzhou, , China
Site reference ID/Investigator # 94518
Shanghai, , China
Site reference ID/Investigator # 94517
Shanghai, , China
Site reference ID/Investigator # 94516
Shanghai, , China
Site reference ID/Investigator # 94515
Wuhan, , China
Site Reference ID/Investigator# 95908
Alexandria, , Egypt
Site reference ID/Investigator# 95900
Cairo, , Egypt
Site reference ID/Investigator# 95901
El Sharkya, , Egypt
Site reference ID/Investigator# 95902
Giza, , Egypt
Site reference ID/Investigator# 95903
Giza, , Egypt
Site Reference ID/Investigator# 95906
Port Said, , Egypt
Site reference ID/Investigaot# 94525
Guadalajara, , Mexico
Site refernce ID/Investigator# 94527
Mexico City, , Mexico
Site reference ID/Investigator# 94523
Tampico, , Mexico
Site reference ID/Investigator# 85314
Bialystok, , Poland
Site Reference ID/Investigator# 85297
Bialystok, , Poland
Site Reference ID/Investigator# 85298
Bydgoszcz, , Poland
Site Reference ID/Investigator# 85293
Katowice, , Poland
Site Reference ID/Investigator# 85296
Lodz, , Poland
Site reference ID/Investigator# 85313
Olsztyn, , Poland
Site Reference ID/Investigator# 85295
Poznan, , Poland
Site Reference ID/Investigator# 85294
Poznan, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P13-678
Identifier Type: -
Identifier Source: org_study_id